Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Abstract Background Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. However, risk factors for cardiac toxicity remain unclear. Our objective wa...

Full description

Bibliographic Details
Main Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Shelton L. Harrell, Robert F. Cornell
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Cardio-Oncology
Subjects:
Myeloma
Bortezomib
Carfilzomib
Proteasome inhibitors
Risk factors
Cardiotoxicity
Online Access:http://link.springer.com/article/10.1186/s40959-017-0023-9

Internet

http://link.springer.com/article/10.1186/s40959-017-0023-9

Similar Items